Allergy Immunotherapy Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Allergy Immunotherapy Market in 2025 is estimated at USD 1.99 billion. The global Market size was worth over USD 1.85 billion in 2024 and is poised to grow at a CAGR of around 9.5%, reaching USD 6.02 billion revenue by 2037. Asia Pacific is anticipated to yield USD 2.17 billion by 2037, fueled by large proportion of the younger population and uptake of immunotherapy medicines.
Because more people are developing these allergies, the market is expanding. The healthcare system is challenged by complex allergies, which cause people's health to deteriorate too much. Asthma and other allergies that affect the body's respiratory system are on the rise as a result of the environment's increasing air pollution. As per a recent report, asthma was the primary diagnosis in 38,792 hospitalizations between 2017 and 2018. Also, Asthma-related fatalities totaled 417 in 2020.
Furthermore, a rising number of immunotherapy treatments are under development to treat patients' allergies. This element is anticipated to fuel market expansion. Sublingual immunotherapy has been investigated by certain researchers for a variety of food allergies, including those to milk, peanuts, kiwis, and peaches. Numerous studies have shown that therapy cannot be effective without consistent pharmaceutical use.
Allergic Immunotherapy Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Research and Development Activities - Increasing investments and financial support in the study of these allergies and the development of effective treatments for them. The market is expanding as a result of this. Immune Therapeutics is creating the biologic immunotherapy experimental medication AR101 for people with a peanut allergy.
- Growing Prevalence of Allergies – An individual's quality of life is negatively impacted by allergic diseases because they disrupt many physiological processes. The demand for an efficient treatment method like allergy immunotherapy is growing due to the rising prevalence of allergies among people around the world as a result of increased exposure to numerous allergens such as pollens, mists, moulds, and others. For instance, in the US, about 25.7% of adults will have seasonal allergies by 2023, and about 31.8% of adults will have an allergy. This element is fueling market expansion.
- Increasing Demand for Advanced Procedures – Pharma companies are able to expand their treatment options due to the rising prevalence of allergies and the ensuing medical therapies. Players are improving the already effective SLIT medications, which have been shown to treat atopic dermatitis, respiratory allergies, and a few food allergies. According to recent surveys, SLIT is still preferred by consumers over SCIT despite its drawbacks because of its accessibility. Additionally, a 10% annual increase in the prevalence of food allergies has been documented, which has increased the demand for immunotherapy for food allergies.
Challenges
- Side Effects of Subcutaneous Injections – Patients do experience some alleviation from the subcutaneous injections, but there are some negative effects as well. The couple's adverse effects are anticipated to be hampered by these negative effects. During the projection period, these adverse consequences are anticipated to hurt the market.
- Limitations Associated with Applicability of Allergy Immunotherapy
- Poor Efficacy and Specificity of Immunotherapy
Allergy Immunotherapy Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.5% |
|
Base Year Market Size (2024) |
USD 1.85 billion |
|
Forecast Year Market Size (2037) |
USD 6.02 billion |
|
Regional Scope |
|
Allergy Immunotherapy Segmentation
Allergy Type (Allergic Rhinitis, Asthma, Allergic Conjunctivitis)
The rhinitis segment is expected to hold a significant share of the allergy immunotherapy market during the forecast period. According to a survey, rhinitis and asthma impact 23 million people in the US each year. In the same region, an additional 50 million people suffer from another type of allergy. One of the major drivers of the market expansion is the increased investment made by major manufacturers in the development of AIT medications to treat different allergies. Therefore, it is anticipated that allergic rhinitis will fuel the segment's expansion.
Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy)
The subcutaneous immunotherapy segment would account for more than 53% of the allergy immunotherapy market. Subcutaneous immunotherapy (SCIT) is a cutting-edge method for treating allergic diseases because it alters allergic diseases by concentrating on the underlying immunological mechanism. Numerous carefully monitored clinical trials have demonstrated its efficacy and safety in the treatment of asthma, allergic rhinitis/rhino conjunctivitis, and hypersensitivity to stinging insects. Subcutaneous immunotherapy (SCIT), which is administered via injection, is frequently referred to as an "allergy shot". It provides symptomatic relief for those with asthma and allergic rhinitis and is the standard treatment for allergen desensitization. Increased prevalence of allergic disorders and high demand for improved procedures are some of the factors driving the growth of the segment. According to estimates, between 11 and 26 million people in Europe have food allergies. With a population of 7 billion people, this rate amounts to 240–550 million people who could be food allergies, which is a significant global health burden.
Our in-depth analysis of the global market includes the following segments:
|
Treatment |
|
|
Allergy Type |
|
|
Distribution Channels |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAllergy Immunotherapy Industry - Regional Synopsis
APAC Market Forecast
By the end of 2037, Asia Pacific region is estimated to hold allergy immunotherapy market share of over 36%. In countries, such as India and China, this is mainly due to the existence of a large proportion of the younger population that are more susceptible to sensitization. Moreover, a number of factors contributing to market growth in the presence of major key players, investment from them, and uptake of medicines like Sublingual Immunotherapy with an overview of long-term results as well as dosage standardization.
North American Market Statistics
North America allergy immunotherapy market is expected to hold a significant share of 27% during the forecast period, attributed to the region's high frequency of allergy diseases as well as the population's increased health consciousness. According to the World Allergy Organization, allergic rhinitis is the seventh most common chronic respiratory condition in the US, affecting 10–30% of the general adult population and approximately 405 children. A few other elements boosting the expansion in the area include high-end research and development, investments made by market participants, partnerships and acquisitions with significant industry participants, and strong emphasis on manufacturing facilities.
Companies Dominating the Allergic Immunotherapy Landscape
- ALK
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Stallergenes Greer
- Mylan N.V.
- HAL Allergy B.V.
- LETIPharma
- AstraZeneca
In the News
- September 2023 - As a top provider of allergen immunotherapy (AIT), Stallergenes Greer has secured agreements with Nestlé on a global scale to use the oral immunotherapy drug Palforzia® to treat peanut allergy.Upon signing, the deal was finalized.
- June 2023 – ALK recently released the preliminary findings from a Phase 3 pediatric clinical trial evaluating a sublingual allergy immunotherapy pill for the treatment of allergic rhinitis brought on by house dust mites (HDM). The HDM tablet is sold under the names MITICURETM in Japan, ODACTRA® in the USA, and ACARIZAX® in Europe and other international markets.
Author Credits: Radhika Pawar
- Report ID: 3769
- Published Date: May 08, 2025
- Report Format: PDF, PPT
